Multiple combinations of immunotherapy and chemotherapy have been looked at, explains Gentzler. The KEYNOTE-189 trial looked at pembrolizumab (Keytruda) plus chemotherapy in patients with nonsquamous NSCLC and showed a survival benefit with the addition of pembrolizumab. The KEYNOTE-407 trial was a similar study that enrolled patients with squamous cell lung cancer that looked at platinum-doublet chemotherapy plus pembrolizumab. That study also showed a survival improvement. The combination of chemotherapy plus atezolizumab (Tecentriq) plus bevacizumab (Avastin) has also shown an improvement in overall survival compared with chemotherapy alone, notes Gentzler.

Physicians also have data from immunotherapy combinations. The CheckMate-227 trial compared ipilimumab (Yervoy) and nivolumab (Opdivo) with chemotherapy alone in a subset of patients who have a high tumor mutational burden. The trial showed an improvement in progression-free survival (PFS) with the combination. The CheckMate-227 trial had multiple arms, and one of the subsets that was looked at was the low PD-L1 expression group in which chemotherapy plus nivolumab was compared with chemotherapy alone. There was also an improvement in PFS within that comparison group, adds Gentzler.

Multiple combinations of immunotherapy and chemotherapy have been looked at, explains Gentzler. The KEYNOTE-189 trial looked at pembrolizumab (Keytruda) plus chemotherapy in patients with nonsquamous NSCLC and showed a survival benefit with the addition of pembrolizumab. The KEYNOTE-407 trial was a similar study that enrolled patients with squamous cell lung cancer that looked at platinum-doublet chemotherapy plus pembrolizumab. That study also showed a survival improvement. The combination of chemotherapy plus atezolizumab (Tecentriq) plus bevacizumab (Avastin) has also shown an improvement in overall survival compared with chemotherapy alone, notes Gentzler.

Physicians also have data from immunotherapy combinations. The CheckMate-227 trial compared ipilimumab (Yervoy) and nivolumab (Opdivo) with chemotherapy alone in a subset of patients who have a high tumor mutational burden. The trial showed an improvement in progression-free survival (PFS) with the combination. The CheckMate-227 trial had multiple arms, and one of the subsets that was looked at was the low PD-L1 expression group in which chemotherapy plus nivolumab was compared with chemotherapy alone. There was also an improvement in PFS within that comparison group, adds Gentzler.